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Protein transportevelopment takes place at the expanded anterior end of the neural tube, which is
ﬁlled with embryonic cerebrospinal ﬂuid (E-CSF). Most of the proteins contained within the E-CSF, which
play crucial roles in CNS development, are transferred from the blood serum. Two important questions are
how E-CSF is manufactured and how its homeostasis is controlled. In this respect, the timing of the blood–
CSF barrier formation is controversial. Recently, the concept of a functional dynamic barrier has been
introduced. This type of barrier is different from that found in adults and is adapted to the speciﬁc require-
ments and environment of the developing nervous system. In this study, we injected a number of proteins
into the outﬂow of the heart and into the cephalic cavities and examined their transport rate between these
two embryo compartments. The results indicated that a functional blood–CSF barrier dynamically controls E-
CSF protein composition and homeostasis in chick embryos before the formation of functional choroid
plexuses. We also showed that proteins are transferred through transcellular routes in a speciﬁc area of the
brain stem, close to the ventral mesencephalic and prosencephalic neuroectoderm, lateral to the ventral
midline, in particular blood vessels. This study contributes to our understanding of the mechanisms involved
in CNS development, as this blood–CSF interface regulates the composition of E-CSF by regulating its speciﬁc
composition.
© 2008 Elsevier Inc. All rights reserved.IntroductionIn vertebrates, early brain development takes place at the
expanded anterior end of the neural tube. The development of the
central nervous system (CNS) involves the simultaneous and inter-
dependent action of several developmental mechanisms, including
the establishment of positional identities, morphogenesis and
histogenesis. These mechanisms are regulated by transcription factors
as well as by diffusible molecules such as growth factors and mor-
phogens acting in an autocrine/paracrine manner. Just after the
closure of the anterior neuropore, the brain wall is formed by a pseu-
domonostratiﬁed neuroepithelium that is mainly made up of
pluripotent neuroepithelial progenitor cells. This wall encloses a
large cavity containing embryonic cerebrospinal ﬂuid (E-CSF). At this
developmental stage–between embryonic days E3 and E4 in chick
embryos (which corresponds to developmental stages HH20 to HH23
according to Hamburger and Hamilton (1951))–the highly dynamic
cellular behaviour of the neuroepithelial cells forming the brain wall
includes both intense proliferation and the initiation of a period
characterised by a high rate of neurogenesis. E-CSF, which is initially
formed by trapped amniotic ﬂuid, is in contact with the apical surface
of all the neuroepithelial cells of the cephalic vesicles. Thus, al rights reserved.physiologically sealed system is formed, with a complex and dynamic
protein composition that differs from that of embryonic serum (E-
serum) (Gato et al., 2004). E-CSF has several crucial roles in brain
anlagen development: (1) it exerts positive pressure against the
neuroepithelial walls and generates an expansive force (Alonso et al,
1999, 1998; Desmond and Jacobson, 1977; Jelinek and Pexieder, 1970;
Miyan et al., 2003); (2) it contributes to regulating the survival, pro-
liferation and neurogenesis of neuroectodermal stem cells (Gato et al.,
2005); and (3) it collaborates with a well-known organising centre,
the mes-metencephalic boundary or isthmus (IsO), in the pattern of
neuroepithelial gene expression (Parada et al., 2005a).
At E4, chick E-CSF proteome includes molecules whose role during
the development of systems other than the E-CSF may account for the
general functions of this ﬂuid, as described above (Parada et al., 2006).
Similar proteomes with parallel functions have been reported in
mammals at equivalent developmental stages (Parada et al., 2005b;
Zappaterra et al., 2007; reviewed by Parada et al., 2007). Moreover,
recent studies have implicated certain proteins, lipid fractions and
morphogens contained within the E-CSF (such as FGF2, apolipopro-
teins, retinol binding protein, retinol and low density lipoproteins) in
controlling initial neurogenesis and neuroepithelial cell proliferation
and survival (Martin et al., 2006; Bachy et al., 2008; Parada et al., 2008,
in press).
Most of themolecules identiﬁed in chick E-CSF are not produced by
the neuroectoderm itself, but by other embryonic structures. Alter-
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up by the chorioallantoic membrane (Parada et al., 2006). We recently
demonstrated that most of the major E-CSF protein fractions are
produced or stored outside of the cephalic vesicles (Parvas et al.,
2008), suggesting that they are transported from the producing or
storage site to the E-CSF, probably via the E-serum. Taking into
account the key roles played by E-CSF during these early stages of
brain anlagen development, a question arises. How is the homeostasis
of this intra-cavity ﬂuid controlled, i.e. how and to what extent is the
transport of speciﬁc gene products from the E-serum to the E-CSF and
vice versa controlled?
In adult vertebrates, CNS homeostasis is controlled by the blood-
brain barrier (BBB) in vessels, which impedes transfer from the blood
to the brain of virtually all molecules, except those that are small and
lipophilic and, interestingly, sets of small and large hydrophilic
molecules (e.g. gene products) which can enter the brain via active
transport (Rowland et al., 1992). In embryos, the permeability of the
BBB has usually been determined using what were considered inert
tracers. For example, Wakai and Hirokawa (1978) used horseradish
peroxidase (HRP) to show that capillaries in chick embryos gradually
become impermeable to this molecule from as late as E13. However,
the HT7 antigen, a chick-speciﬁc cell-surface glycoprotein used in
experimental studies as amarker of barrier-provided vessels, has been
detected as early as E6 in rhombencephalon and mesencephalon
(Bertossi et al., 2002). In mouse embryos, the ﬁrst capillaries that
penetrate the neuroectoderm are located in the brain stem of the
mesencephalon and prosencephalon at E10, which corresponds to an
E3.5 chick embryo (Herken et al., 1989).
With respect to CSF composition and homeostasis, in the adult
brain and in foetuses these conditions are tightly regulated by the
choroid plexus, whose epithelial cells establish a blood–CSF barrier
(Mollgard et al., 1979, Tauc et al., 1984). Choroid plexuses are vascular
complexes related to brain ventricles that manufacture CSF by
promoting the transport of some molecules from the blood plasma
and by producing other molecules that are directly delivered to the
brain vesicles. Developing choroid plexuses are ﬁrst detected at E7 in
chick and at E13 in mouse/rat embryos (Bellairs and Osmond, 2005,
Emerich et al., 2005). This means that these organs cannot manu-
facture E-CSF or control its homeostasis at the initiation of primary
brain neurogenesis, when E-CSF is known to play a crucial role in CNS
development.
The permeability of blood–CSF barriers is usually expressed as a
ratio of the concentration of particular molecules in the CSF with
respect to blood plasma. For small molecules this ratio is much higher
in the developing brain than in the adult brain (Ferguson and
Woodbury, 1969 Dziegielewska et al., 1979; Habgood et al., 1993; Ek et
al., 2001). This has been interpreted as evidence of greater barrier
permeability (Johanson, 1989; Kniesel et al., 1996; Engelhardt, 2003;
Lee et al., 2003). However, tight junctions, the morphological basis of
these barriers, are present from the earliest stages of development
between endothelial cells of blood vessels in BBB (Saunders and
Mollgard, 1984) areas, as well as in epithelial cells of the choroid
plexuses in the blood–CSF barrier (Mollgard et al., 1979; Tauc et al.,
1984). Thus, it was recently suggested that different transcellular
mechanisms for protein and small molecule transfer operate across
the embryonic blood–CSF interface (Johansson et al., 2006).
More recently, on the basis of theoretical grounds and extensive
literature, Johansson et al. (2008) argued that the developmental
blood–CSF barrier restricts the passage of lipid-insoluble molecules
such as gene products by the same mechanism as in the adult, i.e. by
tight junctions, rendering the paracellular pathway an unlike route of
entry. They suggest that proteins are transferred through transcellular
routes. Thus, they introduce the concept of a functional and dynamic
barrier, which is different from that of the adult as it is adapted to the
speciﬁc requirements and environment of the early developing
nervous system.In this paper, we focused on protein transfer across the blood–CSF
interface at the beginning of chick brain anlagen neurogenesis, shortly
after the closure of the anterior neuropore. We injected several
different proteins into the outﬂow of the heart (blood serum) and into
the cephalic cavities (E-CSF) and analysed their transfer between
these two embryo compartments. The results indicated a functional
blood–CSF barrier that dynamically controls E-CSF protein composi-
tion and homeostasis in chick embryos from shortly after the closure
of the anterior neuropore. This coincides with the initiation of maxi-
mum neurogenesis and occurs before functional embryonic choroid
plexuses are formed. We also show that proteins are transferred
through transcellular routes in a very speciﬁc area that is lateral to the
brain stem, close to the ventral mesencephalic and prosencephalic
neuroectoderm and lateral to the ventral midline. The particular blood
vessels involved exhibit vascular sprouts that are in close contact with
the neuroectoderm. We argue that this blood–CSF barrier function
regulates the composition of E-CSF. Thus, it contributes to the crucial
role of the E-CSF in CNS development.
Material and methods
Obtaining chick embryos
Fertile chicken eggs were incubated at 38 °C in a humidiﬁed atmosphere to obtain
chick embryos at the desired developmental stage, i.e. at E3 (HH20), E4 (HH23) and E5
(HH26) (E is embryonic day since the beginning of incubation; HH is Hamburger and
Hamilton (1951) developmental stages, as depicted in Bellairs and Osmond, 2005). For
the E5 embryos, on the second day of incubation 2–3 ml of egg white were removed
with a syringe to prevent the chorioallantoic membrane from sticking to the egg shell.
In all cases, a further 4–5 ml of egg white was removed with a syringe prior to embryo
manipulation, and a circular window was opened in the egg shell with sterile scissors.
Before any manipulation, the egg shell was cleaned with a wet alcohol tissue to avoid
contamination.
Microinjection of molecules
Microinjection of the several different molecules used in this study was performed
in ovo with a glass microneedle (30 μm inner diameter at the tip) connected to a
microinjector (Nanoject II) through a small opening made in the extraembryonic
membranes with a sterilised tungsten needle. Molecules were microinjected into the
mesencephalic cavity (10 pulses of 23 nl each) to monitor E-CSF/E-serum transfer, as
this is the largest cavity in the avian brain at this stage of development. Alternatively,
they were injected into the outﬂow tract of the heart (10 pulses of 23 nl each) to
monitor E-serum/E-CSF transfer. Injections were always made on embryos at E4
(HH23), unless otherwise stated. The following molecules were microinjected:
horseradish peroxidase (HRP; Sigma 6782, at 50 mg/ml; mw 40 kDa); bovine serum
albumin (BSA; Sigma B4287, at 50 mg/ml; mw 66 kDa); immunoglobulins (IgG anti-
BSA; Sigma B2901, at 34 mg/ml of total protein content, from which 5.5 mg/ml
corresponds to the speciﬁc antibody; mw 180 kDa); myosin heavy chain from rabbit
(MHC; Sigma, M7659, at 5mg/ml; mw 200 kDa); human recombinant ﬁbroblast growth
factor no. 2 (FGF2), which also contains BSA as a stabiliser (Sigma, F0291; at 0.01mg/ml;
mw 17 to 34 kDa for FGF2); plasma retinol binding protein (RBP; Sigma, R9388, from
human urine, at 0.01 mg/ml; 21 kDa; the recombinant protein glutathione-S-
transferase (from Schistosoma japonicum) alcohol dehydrogenase (from Drosophila le-
banonensis) (GST-Adh), puriﬁed from bacterial cultures (Martin et al., 2006; at 50 mg/
ml; mw 38 kDa); ovalbumin (Sigma, A7641, at 50 mg/ml; mw 44 kDa); and biotin-
dextran (BDA3000; Molecular Probes, D7135; mw 3000 Da). Prior to microinjection,
FGF2, RBP and GST-Adh were labelled with FITC; ovalbumin was labelled with either
FITC or Evitag® nanocrystals; and BSA was labelled with Evitag® nanocrystals or was
injected unlabelled (see below for protein labelling). Proteins were dissolved in saline
solution, to which fast green was added (1/5) to visualize the microinjection.
Coupling of proteins to FITC and Evitag® nanocrystals
Commercial FGF2, RBP and ovalbumin, as well as GST-Adh fusion protein, were
coupled to ﬂuorescein isothiocyanate isomer I (FITC, Sigma; FITC-1 conjugation Kit) so
that they could be distinguished from the corresponding endogenous molecules during
their detection (for FGF2, RBP and ovalbumin), or simply so that they could be easily
detected (for GST-Adh) with an anti-FITC antibody. The coupling was made according to
Sigma standard protocol, which is based on the protocol described by Harlow and Lane
(1988). The unbound dye was separated by gel ﬁltration. Molecules coupled to FITC
were named FGF2-, RBP-, ovalbumin- and GST-Adh-FITC respectively.
Commercial ovalbumin and BSA were also coupled to Evitag® nanocrystals
(Adirondack Green; Evident Technologies) according to the instructions of the supplier
(http://www.evidenttech.com). An excess of ovalbumin and BSA (×2 with respect to
standard protocols) were used so that there would be no unbound Evitags®. Molecules
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respectively.
Obtaining embryonic ﬂuids
To detect the ratio of molecule transfer between the blood stream and the cephalic
cavities and vice versa, as well the allantoic ﬁltration of these molecules in some cases,
E-CSF, E-serum and allantoic ﬂuid were obtained at several different times after
microinjection: 0 min, 5 min, 10 min, 20 min, 1 h and 24 h. Embryos were always
microinjected at E4 (HH23), except otherwise stated. In the same way, to detect the
relative concentration in the E-serum and E-CSF of some endogenous proteins (RBP,
FGF2, ovalbumin and IgY) at different stages around the initiation of primary
neurogenesis, E-CSF and E-serum were obtained from E3 (HH20), E4 (HH23) and E5
(HH26) control embryos. To obtain E-CSF, the embryos were dissected out of extra-
embryonic membranes, rinsed twice in sterile saline solution and placed in a Petri dish.
A glass microneedle (30-μm inner diameter at the tip) connected to a microinjector
(Nanoject II) was carefully placed in the middle of the mesencephalic cavity under
dissecting microscope control. E-CSF was slowly aspirated, avoiding contact with the
neuroepithelial wall so as to obtain samples that were not contaminated by
neuroepithelial cells. Enough embryos were used to obtain an adequate amount of E-
CSF. To minimize protein degradation, E-CSF samples were kept at 4 °C during this
procedure and immediately frozen at −20 °C until use.
Both E-serum and allantoic ﬂuid were obtained in ovo. After opening a small
window in the eggshell, the chorioallantoic membrane was dissected with a tungsten
needle. The blood was obtained by microaspiration carried out in the outﬂow tract of
the embryonic heart. The allantoic ﬂuid was obtained by microaspiration in the
allantoic vesicle, as described above for E-CSF. The embryo was held by placing a small
sterile spatula underneath it. To minimize protein degradation, samples were kept at
4 °C during this procedure. Blood and allantoic ﬂuid from different embryos were
pooled and immediately centrifuged, and both samples were stored at −20 °C until use.
SDS-polyacrylamide gel electrophoresis, western-blot and slot-blot analysis
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed under dena-
turing conditions according to the method of Laemmli (1979), with a Miniprotean II
electrophoresis system (Bio-Rad). Ovalbumin, ovalbumin–Evitag, BSA and BSA–Evitag
(to monitor Evitag labelling), as well as E-CSF and E-serum of embryos microinjected
with FGF2-FITC (to distinguish FGF2-FITC from the BSA-FITC generated during the
coupling, as commercial FGF2 is sold stabilised with BSA) were used. Molecular mass
standards of high and low range (Bio-Rad) were also used. SDS-PAGE was performed in
a discontinuous buffer system for 40 min at 100 V. When needed, samples were stained
with Coomassie Blue or with a Silver Stain Kit (Bio-Rad), following standard procedures.
For the western-blot analysis, proteins were electrotransferred (Trans-Blot Transfer
System, Bio-Rad) from the SDS-PAGE to activated nitrocellulose membrane (Hybond-N)
for 1 h at 100 V, using a basic transfer buffer following standard protocols. Detection of
proteins after western-blot was performed as described below for slot-blot analysis.
For the slot-blot analysis, embryonic ﬂuids were applied to nitrocellulose mem-
brane (Hybond-N) using a microsample ﬁltration manifold (Schleicher and Schuell, SRC
072/0) connected to a vacuum pump. Slot-blot was used to detect all of the
microinjected molecules in the analysed embryo ﬂuids except FGF2-FITC, i.e. HRP,
BSA, immunoglobulins, MHC, GST/Adh-FITC, Ovalbumin-FITC, RBP-FITC and BDA3000
at several different dilutions. This procedure was also used to detect endogenous oval-
bumin, RBP and IgY within the E-CSF and the E-serum, and the embryonic/extra-
embryonic origin of the several protein fractions obtained with silver staining of E-CSF
SDS-PAGE (see above). After sample application, membranes were dried to ﬁx the
proteins, and the presence of molecules was detected. The presence of HRP was
detected directly by developing the slot-blot with 3-3′-diaminobenzidine tetrahy-
drochloride (DAB; 25 mg of DAB in 50 ml of PBS, 1 ml of CoCl2, and 5 μl of H2O2 30% in
the dark). The reaction was stopped by washing the ﬁlters with distilled water (×3).
For other microinjected proteins, membranes were blocked in 5% powdered
defatted milk in PBT (MTP) for 2 h at room temperature with gentle shaking, except for
samples containing BSA, which were blocked in PBT alone to avoid crossreaction. The
membrane was then incubated with the corresponding primary antibody, which was
properly diluted in MTP, overnight at 4 °C, except for samples containing BSA, in which
the primary antibody was diluted just in PBT: i.e. mouse anti-BSA (Sigma, B2901) at 1/
3000; mouse anti-MHC (Bueno et al., 1997) at 1/500; mouse anti-FITC (Sigma, F5636) at
1/2500; mouse anti-RBP (Labvision MS-428 at 1/3000; rabbit anti-ovalbumin
(Calbiochem, 126705) at 1/1000; and rabbit anti-FGF2 (Sigma, F3393) at 1/2000.
After primary antibody incubation, membranes were washed with PBT (4×15 min)
at room temperature, and subsequently incubated with the appropriate secondary
antibody diluted in MTP for 2 h at room temperature: i.e. goat anti-mouse or
alternatively goat anti-rabbit conjugated to HRP (Sigma, A0168 and A0545 respectively)
at 1/3000. To detect the microinjected IgGs, membranes were incubated with the
proper secondary antibody. To detect BDA3000, membranes were incubated with
avidin–biotin complex kit coupled to HRP (Sigma). To detect the presence of IgY,
membranes were incubated with the proper secondary antibody, anti-chicken IgY
conjugated to HRP (Sigma, A-9046). Finally membranes were washed with PBT
(4×15min) at room temperature, developedwith DAB, and analysed as stated above for
HRP. The reaction time and sample dilution for each molecule was empirically
determined to obtain the appropriate contrast with no background. The relativeconcentrations of these molecules were calculated using Scion Image software on the
scanned slot (or western) blots, on the basis of the highest immunoreaction for each
speciﬁc experiment, expressed as a ratio of the concentration.
Immunohistochemistry
To detect the protein transfer site(s), some embryos were killed 10 to 20 min after
protein microinjection, dissected out of the extraembryonic membranes and ﬁxed in
paraformaldehyde 4% for confocal microscopy. Then, they were embedded in 5%
agarose/10% sucrose in PBS and stored overnight at 4 °C. Subsequently, they were cut
into 200 μm sections with a vibratome (Vibratome 1000 Plus). Some embryos were also
immunodetected by cutting them sagittally in two halves with a scalpel. They were
then washed with PBT (2×1 h, PBS+0.1% Triton X-100, from Sigma) and blocked in 10%
foetal calf serum (FCS) in PBT for 1 h at room temperature. Embryos in which BSA had
been microinjected were blocked with PBT alone to avoid antibody crossreaction. Then,
they were incubated for 2 to 3 days at 4 °C with the corresponding primary antibody
(mouse anti-FITC, Sigma F5636, at 1/2500; mouse anti-BSA, Sigma B2901,1/1000). After
being washed in PBT (3×1 h), they were incubated with the proper secondary antibody
(anti-mouse conjugated to Alexa-488 at 1/500, Molecular Probes A11029). For BDA3000
microinjected embryos, the samples werewashed with PBT (3×1 h) and then incubated
with Streptavidin-Alexa488 at 1/500 (Molecular Probes A11029), for 90 min at room
temperature. Samples from ovalbumin-Evitag and BSA-Evitag microinjected embryos
were simply washed with PBT (2×20 min).
Sections and half-mount embryos were counterstained with phalloidin-TRITC at 1/
2000 (Sigma, P1951) and/or with TOTO-3 at 1/1000 (Molecular Probes, T3604) in the
presence of 1% Rnase (Sigma, R6513) overnight at 4 °C. After washing with PBT (3×1 h),
samples were mounted on slides with Glycerol–PBS 1:1 v/v. All incubations were made
whilst gently shaking. Photomicrographs were taken using a confocal microscope
(Olympus) or with a dissecting microscope equipped with epiﬂuorescence (Leica
MZ16F) and were assembled with Photoshop software.
For immunohistochemistry on semithin sections, embryos in which BSA had been
microinjected in the cephalic vesicles were ﬁxed in paraformaldehyde 4%–glutaralde-
hyde 0.1%. The area of protein transfer was dissected from the rest of the embryo,
embedded in Lowicryl HM20 by freeze substitution, and then sectioned. The presence
of transported BSAwas detectedwith anti-BSA speciﬁc antibody (see above), which was
subsequently detected with an anti-mouse gold antibody (10 nm gold particles; Sigma
G7652). The signal was ampliﬁed using the LM/EM silver enhancing kit (British Biocell
International, BBI-SEKL 15). Finally, immunostained semithin sections were counter-
stained with 0.1% toluidine blue.
Organotypic cultures of neuroepithelium
Organotypic cultures of both dorsal and ventral mesencephalic neuroepithelium
were developed basically as described in Gato et al. (2005). Brieﬂy, chick embryos at E4
(HH23) were dissected out of extraembryonic membranes, and the ectoderm covering
the mesencephalic vesicle was removed using a tungsten needle. Subsequently, the
mesencephalic roof, or the ventral mesencephalon, was cut with microscissors. After
extensive washing in a serum-freemedium, the explants were placed on small pieces of
Millipore ﬁlters (0.8-μm pore size), which had been boiled in distilled and deionised
water. After equilibrating the ﬁlters in a serum-free medium for 15 min, the explants
were positioned on them so that the apical surface was in close contact with the ﬁlter.
To avoid detachment of the explants, they were peripherally ﬁxed to the ﬁlter with a
tungsten needle. They were then transferred to a culture well containing a serum-free
medium (DMEM F12, Sigma) supplemented with 1% ascorbic acid. Then, a 23 nl drop of
RBP-FITC or the solvent was placed on top of the mesoderm covering the ectodermal
explant, using a microinjector (Nanoject II). Ten minutes after the protein had been laid
out, the explants were processed for immunohistochemistry, immunodetected and
photomicrographed as described (see above).
Results
Permeability of the cephalic neuroectoderm
To test the functional effectiveness of the putative chick embryonic
blood–CSF interface just after closure of the anterior neuropore, i.e. to
check the permeability of the cephalic neuroectoderm, a small-sized
tracer (BDA3000) was microinjected into the cephalic cavity or into
the outﬂow of the heart of embryos at E3 (HH20) and E4 (HH23). First
of all, we analysed whether BDA3000 was transferred from the blood
to the E-CSF and vice versa. E-serum and E-CSF were removed 20 min
after BDA3000 microinjection, and the presence of this tracer was
monitored by slot-blot (Figs. 1A, B). When BDA3000 was micro-
injected into the outﬂow of the heart of either E3 or E4 embryos, it was
detected in both the E-serum and the E-CSF. In the same way, 20 min
after BDA3000microinjection into the cephalic vesicles, BDA3000was
also detected within both the E-CSF and the E-serum of both E3 and E4
Fig. 1. Permeability of the embryonic blood–CSF interface at E3 and E4. (A) Bar chart showing BDA3000 transfer from the blood stream to the cephalic cavities 20 min after
microinjection into the outﬂow of the heart. (B) Bar chart showing BDA3000 transfer from the brain cavities to the blood stream 20min after microinjection into the cephalic cavities.
(C) Negative control of dorsal mesencephalic neuroepithelium for an E3 embryo. (D) Dorsal mesencephalic neuroepithelium of an E3 embryo 20 min after BDA3000 microinjection
into the cephalic cavities. (E) Magniﬁcation of the apical pole of the neuroepithelium shown in panel D. Note that the tracer is only present in the cytoplasm of the neuroepithelial
cells (arrows). (F) Magniﬁcation of the basal pole of the neuroepithelium shown in panel D. Note that the tracer is only present in the cytoplasm of the neuroepithelial cells (arrow).
(G) Dorsal mesencephalic neuroepithelium of an E4 embryo 20 min after BDA3000 microinjection into the cephalic cavities. Note the absence of the tracer within dorsal
neuroepithelial cells. (H) Ventral mesencephalic neuroepithelium lateral to the ventral midline of an E4 embryo 20 min after BDA3000 microinjection into the cephalic cavities. Note
the presence of the tracer within the cytoplasm of some neuroepithelial cells and in the adjacent mesenchyma (arrows). (I) Ventral neuroepithelium lateral to the ventral midline of
an E4 embryo 20 min after BDA3000microinjection into the cephalic cavities. Note the presence of the tracer within the cytoplasm of neuroepithelial cells (arrow) and in the vicinity
of a blood vessel located within the mesenchyma (arrowhead). (J) Magniﬁcation of I, showing the presence of BDA3000 within neuroepithelial cells' cytoplasm including the
cytoplasmic processes (arrows). All images were takenwith a confocal microscope. BDA3000 is shown in green; TOTO3 nuclei counterstaining is shown in blue; and phalloidin tissue
contrast is shown in red. The bar charts show the standard error. Five individual experiments were performed for each condition. Scale bars: C, D, G, H and I, 0.05 mm; E, F and J,
0.02 mm. Abbreviations: bc, brain cavity; m, mesenchyma; n, neuroectoderm.
54 M. Parvas et al. / Developmental Biology 321 (2008) 51–63embryos. In the ﬁrst experiment, the relative concentration of the
tracer was approximately 2-fold higher in the E-serum than in the
E-CSF, whereas in the second experiment it was approximately 4-fold
higher in the E-CSF than in the E-serum.
Then, to check whether this inert tracer was being transported
across the neuroepithelial cells through a transcellular route or
whether it crossed the neuroectoderm through extracellular spaces
(i.e. to verify whether the brain cavity was physiologically sealed at
these developmental stages), the microinjected embryos were
processed for immunohistochemistry to monitor the location ofBDA3000 within the neuroectodermal tissue. At E3 (Figs. 1C–F) the
tracer was clearly visible in most, if not all, neuroectodermal cells of
the neuroepithelium of the distinct cephalic vesicles. Interestingly, it
was always detected inside cell cytoplasm and throughout cytoplas-
mic processes, from the apical to the basal pole of the neuroepithelium
(at this stage the neuroepithelium is organised as a pseudomonos-
tratiﬁed tissue). It was never observed within extracellular spaces. It
was also observed within the mesenchymal cells adjacent to the basal
pole of the neuroectoderm. Similarly, at E4 (Figs. 1G–J) when the
tracer was injected either into the vesicles or into the outﬂow of the
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out the cytoplasmic processes, and never in extracellular spaces.
However, unlike the results for E3 embryos, the area of transport was
restricted to a very speciﬁc zone, which was located in the ventral
mesencephalic neuroepithelium lateral to the ﬂoor plate, in the brain
stem. No other neuroepithelial sites in the cephalic neuroectoderm
showed the presence of this tracer. It was also observed within
mesenchymal cells adjacent to the basal pole of the neuroectoderm.
Interestingly, the areas of BDA3000 transfer across the neuroepithe-
lium were always close to blood vessels immersed within the mesen-
chyma (Fig. 1I). Taken together, these results indicate that during CNS
development the cephalic cavities are physiologically sealed at least
from E3 onwards. In addition, in the developmental period between
E3 and E4, the area for blood–CFS transfer (and vice versa) for this
tracer becomes restricted to a very speciﬁc zone.
Blood–CSF physiological transfer of endogenous proteins
The next step was to assess whether at the beginning of primary
neurogenesis the embryonic blood–CSF interface selectively transfers
proteins from the blood stream to the cephalic cavities or whether
they are transferred by free diffusion (i.e. to test whether transport
between the E-serum and the E-CSF is regulated). To achieve this, we
checked the relative concentration in these two embryonic compart-
ments of speciﬁc endogenous proteins that are known not to be
produced by the cephalic neuroectoderm even though they have been
detected within the E-CSF. These proteins were ovalbumin and RBP
(Parada et al., 2006). An interval around E4, i.e. from E3 to E5, was
analysed by slot-blot using speciﬁc antibodies. At all analysed dev-
elopmental stages, ovalbumin, which is known to be taken from the
egg reservoir, was detected at an approximately 2-fold higher
concentration in the E-serum than in the E-CSF (Fig. 2A). Conversely,
the relative concentration of RBP, which may be produced in the liver
primordium and/or in the chorioallantoic membrane, varies with timeFig. 2. Relative concentration of endogenous proteins in the E-serum and in the E-CSF at E3
binding protein (RBP). (C) Bar chart for ﬁbroblast growth factor no. 2 (FGF2). (D) Bar chart
condition.(Fig. 2B). At E3, the relative concentration of this molecule was
approximately 2-fold higher in the E-serum than in the E-CSF.
However, at E4 it was almost 3-fold higher in the E-CSF than in the
E-serum. Finally, at E5 its relative concentration was again slightly
higher in the E-serum than in the E-CSF.
We also tested the relative concentration of endogenously
produced FGF2, a molecule that is known to be produced by several
different embryo tissues and organs, such as the liver primordium, the
notochord, the mesonephros and the neuroectoderm, although the
level of expression in neuroectoderm is much lower than in the other
tissues. Moreover, FGF2 is known to be transferred from the E-serum
to the E-CSF (Martin et al., 2006). The relative concentration of FGF2
was also stage-dependant, although its dynamics were different to
those of RBP. In this case, the relative concentration of FGF2was 2 to 3-
fold higher in the E-CSF than in the E-serum of both E3 and E4
embryos (Fig. 2C). However, at E5 its relative concentrationwas 3-fold
higher in the E-serum than in the E-CSF.
Finally, we checked the relative concentration of IgY, a molecule
that is taken from the egg reservoir in these early developmental
stages and that has not been detected within the E-CSF by proteome
analysis (Parada et al., 2006). IgY was detected in the E-serum in all
analysed stages, and its relative concentrationwas higher in E4 and E5
embryos than in E3 ones. However, it was never detected within the E-
CSF (Fig. 2D). Taken together, these results indicate that the transfer
across the blood–CSF interface of proteins that are normally present
within the embryo ﬂuids is developmentally regulated and that this
regulation depends on each speciﬁc protein, suggesting the existence
of active protein transport from E-serum to E-CSF.
Blood–CSF transfer of heterologous microinjected proteins
To further test the existence of active protein transport from E-
serum to E-CSF and vice versa in chick embryos at E4 (HH23), we
checked the transfer dynamics of a number of exogenous micro-, E4 and E5 developmental stages. (A) Bar chart for ovalbumin. (B) Bar chart for retinol
for IgY. Standard error is shown. Five individual experiments were performed for each
56 M. Parvas et al. / Developmental Biology 321 (2008) 51–63injected proteins. Two different categories of proteins were used for
themicroinjections: (1) proteins that are not normally present in chick
embryos and/or within the analyzed ﬂuids (heterologous proteins), i.e.
HRP, BSA, MHC and GST/Adh (GST/Adh was ﬁrst conjugated to FITC to
facilitate its detection); and (2) proteins that are normally present in
the E-CSF and the E-serum of chick embryos at E4, i.e. ovalbumin, FGF2
and RBP, coupled to FITC before the microinjection, in order to
distinguish them from the endogenous proteins (described in the
following section). Mammalian IgG immunoglobulins, whose protein
sequence differs from avian IgY immunoglobulins–although both
types have a globular structure–were also used. These proteins were
chosen to represent a set of differentmolecularweights. In all cases, E4
embryosweremicroinjected either into the outﬂowof the heart or into
the cephalic cavities in ovo. E-serum and E-CSF were collected atFig. 3. Transfer dynamics of non-avian microinjected proteins. Line charts showing the tran
cephalic cavities. Time is in hours. All embryos were microinjected at E4 (HH23). Continuou
combined dashed and dotted line, relative concentration of allantoic ﬂuid. Microinjected m
shown. Five individual experiments were performed for each condition. Abbreviations are adifferent incubation times aftermicroinjection, from 0 to 24 h. In some
cases, the ﬂuid contained within the allantoic vesicle was also
collected. All ﬂuids were analysed by slot-blot except for FGF2 coupled
to FITC. This was analysed by western-blot, as during the FITC linkage
the accompanying BSAwhich is used as a stabilizer by the supplier also
coupled to the tracer. It is important to note that although FGF2 and
RBPwere of humanorigin, theyexhibit a highdegree of homologywith
the corresponding chick proteins. Moreover it has recently been
reported that FGF2 is able to functionally substitute its endogenous
counterpart in vitro (Martin et al., 2006).
With respect to the blood–CSF transfer of heterologous micro-
injected proteins, we ﬁrst analysed HRP transfer as it was classically
used to determine BBB permeability, since it has been traditionally
considered an inert tracer (Figs. 3A, B). When HRP was injected intosfer dynamics of proteins microinjected either into the outﬂow of the heart or into the
s line: relative concentration of E-CSF; dashed line: relative concentration of E-serum;
olecules and the route of microinjection are indicated in each chart. Standard error is
s in the text.
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progressively declined from 0 to 24 h, i.e. from E4 to E5. At E5 it
approximately equalled HRP concentration in the E-CSF. HRP
concentration within the E-CSF increased correspondingly during
this period. This was the expected result for a non-barrier blood–CSF
interface, and coincided with previous reports on BBB permeability at
later developmental stages. However, when HRP was injected into the
cephalic cavities, it remained mostly inside the cavities within the
E-CSF. Very little HRP was detected within the E-serum after 24 h.
Then, we checked whether the transport dynamics of other
proteins that are also not normally present in chick embryos and/or
in the analysed ﬂuids paralleled the results for HRP. We used BSA and
GST/Adh, as they have a similar molecular mass to HRP, and MHC and
IgG, as their molecular mass is clearly higher, although their reported
3D structure is different (i.e. globular for IgG and mostly ﬁbrillar for
MHC). Interestingly, the transport dynamics of these four proteins
completely differed from that of HRP (Figs. 3C–J).
When BSA, GST/Adh or MHC was microinjected into the outﬂow of
the heart (Figs. 3C, E and G) it was never detected within the E-CSF,
and its relative concentration within the E-serum decreased very
rapidly. Twenty minutes after microinjection, these proteins were no
longer detected within the E-serum. Concomitantly, their relative
concentrations within the allantoic ﬂuid increased rapidly during the
same period. This result indicates that, unlike HRP, these proteins are
not transferred from the E-serum to the E-CSF. In addition, they are
removed very rapidly from the blood stream.
In the same way, when these molecules (BSA, GST/Adh and MHC)
were microinjected into the cephalic cavities (Figs. 3D, F and H), their
relative concentration within the E-CSF also decreased with time,
although not as rapidly. The relative concentration of MHC within the
E-CSF dropped to less than a 1/4 just 1 h after microinjection. BSA and
GST/Adh were still detected within the E-CSF 24 h after microinjec-
tion, although the relative concentrations had decreased by a 1/2 for
BSA and a 1/4 for GST/Adh. An analysis of the E-serum and the
allantoic ﬂuid revealed that these molecules were also being removed
very rapidly from the blood stream to the allantoic vesicle, as in most
cases their presence within the E-serum was under the threshold of
detection. Only MHC was transiently detected within the E-serum.
With respect to IgGs (Figs. 3I, J), when they were injected into the
outﬂow of the heart their relative concentration within the E-serum
decreased as reported for BSA, GST/Adh and MHC, although not as
rapidly. Concentrations were just over the threshold of detection 24 h
after microinjection. In this way, their relative concentration within
the allantoic ﬂuid increased proportionally during the same period,
and their presence within the E-CSF was virtually undetectable.
Finally, when IgGs were microinjected into the brain cavities, they
were mostly detected within the E-CSF 24 h after microinjection. Very
few were detected within the E-serum or within the allantoic ﬂuid.
Blood–CSF transfer of microinjected proteins normally present in E-CSF
and E-serum
Then, we analysed the transfer dynamics of some typically
transferred endogenous proteins such as ovalbumin, RBP and FGF2.
We microinjected them into the outﬂow of the heart or into the
cephalic cavities (Figs. 4A–F). These gene products were previously
coupled to FITC, to distinguish them from the endogenous proteins.
When they were microinjected into the outﬂow of the heart, their
concentration within the E-serum rapidly decreased. One hour after
microinjection, the microinjected FGF2-FITC monitored by the con-
jugated FITC was not detected within the E-serum, and the concentra-
tion of RBP-FITC and ovalbumin-FITC had dropped to less than a 1/4.
The relative concentration of thesemicroinjectedmoleculeswithin the
E-CSF increased during the period analysed. However, this increase did
not account for the total decrease in thesemolecules in the E-serum, as
they were removed by the allantoic vesicle.In the same way, when FGF2-FITC, RBP-FITC or ovalbumin-FITC
were microinjected into the cephalic cavities, their concentration
within the E-CSF rapidly decreased. One hour after microinjection, the
relative concentration of all of these proteins had been reduced by
approximately a 1/2, as detected by the conjugated FITC. The relative
concentration of ovalbumin-FITC and RBP-FITC within the E-serum
increased during the study period, although this increase did not
account for the total decrease in the E-CSF, indicating that these
molecules were also being rapidly removed by the allantoic vesicle.
The relative concentration of FGF2-FITCwithin the E-serumwas under
the threshold of detection during the period analysed, also indicating
that these molecules were being rapidly removed by the allantoids.
Microinjection of these molecules into the outﬂow of the heart
should increase their relative overall concentration, at least transi-
ently, in the E-serum. The transfer of these molecules to the E-CSF was
detected. We then checked whether these microinjected molecules
were transferred from the E-serum to the E-CSF instead of the
endogenous ones (i.e. if their overall concentration within the E-CSF
did not increase), or if they were transferred in addition to the
endogenous ones (i.e., if their overall concentration within the E-CSF
did increase or remain constant). In other words, we assessed the
existence of transport regulatory mechanisms controlling the con-
centration of endogenous proteins within the E-CSF.
To achieve this, we microinjected FGF2, RBP and ovalbumin into
the outﬂow of the heart, and we collected the E-CSF and the E-serum
at different times thereafter, including just before microinjection
(0 min), which represents the endogenous relative concentration; just
after microinjection (0 min), which represents the sum of the endo-
genous and injected concentrations; and 5 min, 20 min, and 1 h after
microinjection. Then, we analysed the relative concentration of these
molecules using speciﬁc antibodies (i.e. anti-FGF2, anti-RBP and anti-
ovalbumin) (Figs. 4G–I), thus detecting both the endogenous and the
microinjected molecules. The relative concentration of all molecules
within the E-serum increased just after microinjection. It is important
to note that the immunoreactionwas saturated in all cases. Thus, these
values do not represent the real increase in relative concentration,
which was higher. The justiﬁcation for this is that if we diluted the
samples more, the other values would be under the threshold of
detection.
These experiments showed that the excess of proteins were rapidly
removed from the E-serum, which in 5 min reached a level of relative
concentration that was slightly lower than that detected just before
microinjection. One hour later, all of the analysed proteins had
reached their normal relative concentrations within the E-serum. In
no case did the relative concentrations in the E-CSF increase above
normal values at any time. Conversely, concentrations slightly de-
creased shortly after microinjection, paralleling the dynamics of these
molecules within the E-serum. Again, like their relative concentra-
tions in the E-serum,1 h after microinjection all analysed proteins had
reached their normal relative concentrations within the E-CSF. From
these experiments it can be concluded that these microinjected
molecules are transferred from the E-serum to the E-CSF “instead of”
the endogenous ones, suggesting the existence of concentration
regulatory mechanisms in the blood–CSF interface.
Taken together, these results also suggest that the transfer of
protein molecules across the blood–CSF interface is regulated
differentially, depending on each speciﬁc molecule. In addition, the
allantoids contribute differentially to the elimination of protein
molecules from the blood stream.
Localisation of the protein transfer area(s) in the blood–CSF interface
Finally, we investigated whether the transfer of proteins across the
blood–CSF interface was restricted to a speciﬁc embryo area, as
suggested by BDA3000 transfer experiments at E4. Alternatively, this
transfer could be carried out by any part of the cephalic vesicles and/or
Fig. 4. Transport dynamics of microinjected proteins normally transferred across the blood–CSF interface. (A–F) Line charts showing the transfer dynamics of proteins normally
present within the E-CSF and the E-serum, microinjected either into the outﬂow of the heart or into the cephalic cavities. These proteins were coupled to FITC to distinguish them
from the endogenous ones, and thus theywere detectedwith an antibody to this tracer. (G–I) Bar charts showing the relative concentration of proteins normally present within the E-
CSF and the E-serum after microinjecting such proteins into the outﬂow of the heart to detect to overall increase in concentration in both the E-serum and the E-CSF. Speciﬁc
antibodies were used to detect the sum of the microinjected proteins and the endogenous ones. Time is in hours. All embryos were microinjected at E4 (HH23). Continuous line:
relative concentration of E-CSF; dashed line: relative concentration of E-serum. Standard error is shown. Five individual experiments were performed for each condition.
Abbreviations are as in the text.
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cephalic cavities from within the mesenchyma. Embryos microin-
jected with BSA, ovalbumin-FITC or RBP-FITC were processed forFig. 5. Protein transfer area for blood–CSF interface. Panels A–D and L–M are vibratome sec
microscope. Panels E–H are semithin sections corresponding to ventral mesencephalic neur
whole mount heads seen under an epiﬂuorescence-equipped dissecting microscope. Pan
microscope. Unless otherwise stated, all in ovo experiments were performed bymicroinjectin
were performed by dissecting the neuroectoderm from embryos at E4. Nuclei TOTO3 cou
microinjected into the brain cavities. Note the accumulation of this molecule in the basal mem
of a blood vessel within themesenchyma close to the accumulation site (arrows). (B) Magniﬁc
Note the accumulation of BSA at both their basal and apical poles (arrowheads). (C) Ovalbum
ovalbumin at the basal membrane of the ventral neuroectoderm 20min after microinjection.
to FITCmicroinjected into the outﬂowof the heart. Note the accumulation of RBP at the basal
is also restricted to a speciﬁc area (arrows). (E) Semithin sections of embryos microinjected
sprouts within the neuroectoderm, located at the ventral mesencephalon and at the most an
panel E showing the presence of BSAwithin the endothelium of vascular sprouts (arrow). (G
Evitags® microinjected into the outﬂow of the heart of an embryo at E3 (HH20). Note the ac
20 min after microinjection (arrows). (J) Ovalbumin coupled to Evitags® microinjected in
accumulate at the periphery of the brain cavities. (K) Same embryo shown in panel F after dis
location close tomesencephalic and anterior-most rhombencephalic ventral neuroectoderm
an embryo at E4. Note the presence of ovalbumin–Evitags within some vascular sprouts loc
panel L. Arrows points to the presence of vascular sprouts. (N) Cultured explant of mesencep
been applied. Note the presence of RBP in the mesenchyma (asterisk), within this tissue (arro
the neuroectoderm showing the presence of RBP within its cells. (O) Cultured explant of me
the presence of RBP in the mesenchyma (arrows). This molecule is completely absent from th
bars: A–E, G, L–O, 0.05 mm; F and H, 0.02 mm; I–K, 1 mm. Abbreviations: bc, brain cavity;immunohistochemistry 20 min after microinjection. These proteins
were chosen as we had demonstrated that they were transferred from
the E-CSF to the E-serum or vice versa within this time period. Theirtions corresponding to ventral mesencephalic neuroectoderm seen under the confocal
oectoderm lateral to the ventral midline seen under a light microscope. Panels I–K are
els N–O are vibratome sections of neuroepithelial cultures seen under the confocal
g themolecules into embryos at E4 (HH23). In vitro neuroepithelial explant experiments
nterstaining is shown in blue, and phalloidin tissue contrast is shown in red. (A) BSA
brane of the ventral neuroectoderm 20min after microinjection. Also note the presence
ation of panel A showing the presence of BSAwithin the neuroectodermal cells (arrows).
in coupled to FITC microinjected into the outﬂow of the heart. Note the accumulation of
Also note that this accumulation is restricted to a speciﬁc area (arrows). (D) RBP coupled
membrane of the ventral neuroectoderm 20min after microinjection. This accumulation
with BSA into the cephalic cavities. Note the presence of transported BSA in vascular
terior part of the ventral prosencephalon, lateral to the ﬂoor plate. (F) Magniﬁcation of
) Negative control for panel E. (H) Negative control for panel F. (I) Ovalbumin coupled to
cumulation of ovalbumin–Evitags at different sites in the periphery of the brain cavities
to the outﬂow of the heart of an embryo at E4. Note that ovalbumin–Evitags do not
secting the head in two halves. Note the accumulation of ovalbumin–Evitags at a speciﬁc
(arrow). (L) Ovalbumin coupled to Evitags®microinjected into the outﬂowof the heart of
ated close to mesencephalic ventral neuroectoderm (arrows). (M) Negative control for
halic ventral neuroectoderm lateral to the ﬂoor plate to which RBP coupled to FITC has
wheads) and also within neuroectodermal cells (arrows). The inset is a magniﬁcation of
sencephalic dorsal neuroectoderm to which RBP coupled to FITC has been applied. Note
e neuroectoderm. Five individual experiments were performed for each condition. Scale
bv; blood vessel; m, mesenchyma; mes, mesencephalic vesicle; n, neuroectoderm.
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examine CSF–blood transfer, and ovalbumin and RBP to analyse
blood–CSF transfer.
Twenty minutes after BSA microinjection into the brain cavities, it
was detected at a very speciﬁc location in the brain stem, within the
mesenchyma basal to the neuroectoderm, close to some perineural
blood vessels; speciﬁcally in the ventral mesencephalon and the most
anterior part of the ventral prosencephalon, lateral to the ﬂoor plate
(Fig. 5A). It was also detectedwithin some neuroepithelial cells located
exclusively adjacent to this zone (Fig. 5B), which coincided with the
area of BDA3000 transfer (see Fig. 1). Concomitantly, when either
ovalbumin or RBP coupled to FITCweremicroinjected into the outﬂow
of the heart, their presencewas detectedwithin themesenchyma close
to the basal pole of the neuroectoderm (Figs. 5C, D). In both cases, theintensity of staining was much lower than that for BSA, and could not
be visualised within the neuroectodermal cells. Interestingly, the area
of transfer was also located in the same speciﬁc zone of the ventral
mesencephalon and the anterior-most part of the rhombencephalon,
lateral to the ﬂoor plate. This suggests that at E4 this neuroepithelial
area and the perineural blood vessels close to it constitute the blood–
CSF interface. The immunochemical analysis of semithin sections of
embryos in which BSA had been microinjected into the cephalic
cavities also showed the presence of transported BSA within the
endothelium of vascular sprouts in the neuroectoderm, also located in
the ventral mesencephalon and in themost anterior part of the ventral
prosencephalon, lateral to the ﬂoor plate (Figs. 5E–H).
To check whether the perineural blood vessels close to these
neuroepithelial area were those involved in the blood–CSF interface
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as the size of these ﬂuorescent nanocrystals may hinder or prevent
the transfer of the coupled proteins, favouring their accumulation.
Embryos were processed for histochemistry 20 min after micro-
injection into the outﬂow of the heart. At E3, the autoﬂuorescence of
the accumulated ovalbumin–Evitags® was detected at several
different points all along the periphery of the brain cavities (Fig. 5I
and data not shown), and in the blood vessels surrounding the
cephalic cavities. This suggests that at this developmental stage there
is no speciﬁc area for protein transfer. These results coincide with
BDA3000 transfer experiments at the same developmental stage (see
Fig. 1 for comparison). However, when ovalbumin coupled to
Evitags® was microinjected at E4, the only area in which the
nanocrystals accumulated was the ventral side of the mesencephalon
and the anterior-most part of the ventral prosencephalon, within
blood vessels located close to the neuroectoderm (Figs. 5J, K). These
E4 embryos were also examined after vibratome sectioning and
TOTO3/phalloidin counterstaining, revealing the presence of ovalbu-
min–Evitags® within only some blood vessels and vascular sprouts
located within the mesenchyma, close to the basal pole of the
neuroectoderm, in the ventral mesencephalon and the most anterior
part of the prosencephalon, and lateral to the ventral midline (Figs.
5L, M). Taken together, these results indicate that these blood vessels
are involved in the blood–CSF interface for protein transfer, acting
concomitantly with the adjacent neuroectoderm.
Then, to check whether the capacity of the neuroectoderm to
transfer proteins from the blood stream to the E-CSF at E4 was
restricted to the reported areas of transport, or whether the speciﬁcity
of the transfer areas was only due to the underlying blood vessels and
vascular sprouts, we cultured explants of ventral and dorsal
mesencephalon from E4 embryos. The apical pole of the neuroecto-
derm was placed in contact with the culture medium, which
paralleled the E-CSF within the cephalic cavities, and the basal pole
and some of the underlying mesenchyma was placed on top of the
culture. RBP coupled to FITC was applied onto the mesenchyma. The
explants were processed for immunohistochemistry 10 min after the
protein had been laid out. When RBP was laid onto the mesenchyma
adjacent to the ventral mesencephalic neuroectoderm lateral to the
ﬂoor plate, it was detected within neuroepithelial cells of the
neuroectoderm (Fig. 5N). This suggests that these neuroepithelial
cells were enabled to transfer this protein to the cephalic cavities.
However, when RBPwas laid onto dorsal mesencephalic tissues, it was
never detected within the neuroectoderm (Fig. 5O), suggesting that
these dorsal neuroepithelial cells were not enabled for protein
transfer to the brain cavities. Taken together, these results suggest
that the neuroepithelial cells of the ventral mesencephalon and the
most anterior part of the rhombencephalon exhibit some special
features that enable them for protein transfer from the blood stream
to the E-CSF.
Discussion
Recently, it has been demonstrated that at the beginning of
primary neurogenesis E-CSF contains diffusible factors that contribute
to the control of CNS development, including neuroepithelial
progenitor cell survival, proliferation and differentiation, as well as
brain anlagen growth and morphogenesis (Desmond and Jacobson,
1977; Gato et al., 2005; Parada et al., 2005a). The action on CNS
development of some of the factors contained within E-CSF has been
analysed, including the role of the proteoglycans, FGF2, RBP/all-trans
retinol system, and the apolipoprotein-carried lipids (Alonso et al.,
1999,1998; Martin et al., 2006; Parada et al., 2008, in press). According
to the literature, most of these molecules are produced by tissues
other than the neuroectoderm or they are supplied by the mother
(they cross the placenta in mammals or are taken up from the egg
reservoir by the chorioallantois in avian species). Moreover, it hasbeen demonstrated that most of the major protein fractions contained
within the chick E-CSF at the beginning of brain anlagen neurogenesis
are produced or stored outside of the cephalic cavities (Parvas et al,
2008). This implies that these molecules must be transferred from the
blood serum to the cephalic cavities to manufacture E-CSF. However,
the time of actual barrier formation is somewhat controversial.
Previous studies on blood–CSF interface barrier function, based on the
classical work of Wakai and Hirokawa (1978), showed that blood–CSF
interface permeability to HRP in chick embryos begins to decrease at
E12–E14, i.e. 8 to 10 days after the initiation of primary neurogenesis.
Conversely, two recently published papers (Johansson et al., 2006,
2008) introduced the concept of a functional and dynamic barrier,
which is different from that of an adult and adapted to the speciﬁc
requirements and environment of the early developing nervous
system. These authors also suggested that proteins are transferred
through transcellular routes.
In this paper, we focused on protein transfer across the blood–CSF
interface at the beginning of chick brain anlagen neurogenesis, shortly
after the closure of the anterior neuropore. We have shown that (1)
the cephalic cavities are physiologically sealed at least from E3
(HH20); (2) the E-CSF/E-serum ratio of chick endogenous proteins
produced outside of the cephalic cavities is developmentally regu-
lated; (3) the transfer of both chick endogenous proteins and
microinjected proteins across the blood–CSF interface is tightly
regulated and protein-speciﬁc; and (4) within the period E3 to E4
the transfer of proteins becomes restricted to a speciﬁc embryo area
located at the brain stem lateral to the ﬂoor plate, in the ventral
mesencephalon and the most anterior part of the ventral prosence-
phalon, taking place through speciﬁc perineural blood vessels and
some vascular sprouts within the neuroectoderm at this location.
Transfer of proteins across blood–CSF interface is developmentally
regulated and molecule-speciﬁc
In adult brain, the existence of an endothelial-based BBB has been
recognized for more than 100 years. However, until recently, few
studies applied cellular and molecular biology to this question
(reviewed by Rubin and Staddon,1999). The BBB signiﬁcantly impedes
entry from blood to brain of virtually all molecules, except those that
are small and lipophilic. However, some sets of small and large
hydrophilic molecules, such as proteins, can enter the brain by active
transport. For essential nutrients such as glucose and certain amino
acids, speciﬁc transmembrane transporting molecules are present in
relatively high concentrations in the brain endothelial cells. Some
systems also seem to be capable of shuttling macromolecules into the
brain. Some of these systems are known to be receptor-mediated, e.g.
by the transferrin receptor (Pardridge, 1997). There is evidence that
other growth factors and cytokines have a limited ability to cross the
BBB (McLay et al., 1997).
In adults and foetuses, the CSF ﬁlling brain ventricles and the
subarachnoid space is manufactured by choroid plexuses, which are
epithelial tissues in the brain ventricular system (for a review, see
Johanson, 1995). The choroid plexus is the main component of the
blood–CSF barrier, i.e. the major interface by which many hydrophilic
solutes gain access to the brain from the blood, including proteins and
ions. Acting like a kidney for the brain, the choroid plexus makes a
major contribution to chemical homeostasis and the volume of ﬂuids
bathing neurons and glia. Choroid plexus dysfunction is responsible
for a number of pathological processes, and many neurological
disorders are associated with changes in the chemical composition
of CSF (for review see Johanson, 1995; Johanson et al., 1999a; Miyan et
al., 2003; Rubin and Staddon, 1999).
In embryos, however, nothing is known about the manufacture of
E-CSF, although it has been demonstrated that this ﬂuid plays a crucial
role in early brain development, through the set of speciﬁc proteins
and morphogens it contains (Gato et al., 2005; Parada et al., 2005a,
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the brain anlagen, whose architecture during development is highly
dynamic. At E3 (HH20), just before the start of brain neurogenesis
and when the neuroepithelial cells engage in a very active process of
proliferation, both anterior and posterior neuropores are already
closed. Thus, the E-CSF becomes completely enclosed by the neuro-
ectoderm. It has been reported that from E3 the E-CSF has a complex
protein composition that differs from that of the E-serum, and that the
relative concentration of its proteins vary during development and
with respect to adult CSF (Dziegielewska et al., 1980; Checiu et al.,
1984; Fielitz et al., 1884; Gato et al., 2004).
However, as stated above, the time of the actual barrier formation
is controversial. Despite previous works on the blood–CSF interface
barrier function (Wakai and Hirokawa, 1978) showed that the
permeability of the blood–CSF interface to HRP began to decrease at
E12–E14, an analysis of the expression of a chick-speciﬁc cell-surface
glycoprotein that is speciﬁc to barrier function provided endothelial
cells (neurothelin/HT7) revealed that it is expressed from E6 in
microvessels of the brain stem located in the ventral part of the
rhombencephalon and mesencephalon (Bertossi et al., 2002). At later
stages of development, HT7 is progressively detected in an increasing
number of blood vessels, including the developing choroid plexus
from E10 onwards. From E16, this antigen is uniformly distributed
within the entire brain microvasculature. From these results, Bertossi
et al. (2002) concluded that the HT7 antigen precedes restriction
permeability to tracer HRP.
Conversely, a recent study in which the transport of human and
bovine albumin across the blood–CSF interface was examined in rat
embryos indicated that blood-to-CSF transfer is selective from rat E13
onwards (the CNS development of a rat embryo at E13 corresponds
approximately to that of an E4 to E5 chick embryo). This is in agree-
ment with previous studies demonstrating that in rodent embryos
serum proteins are excluded from the brain at a relatively early stage,
indicating that a protein barrier is present early in development
(Saunders et al 1991; Rubin and Staddon, 1999). In fact, it seems
unlikely that all of the properties of the BBB of the blood–CSF interface
are acquired simultaneously.
In this study, an analysis of the dynamics of the relative
concentration of several chick endogenous proteins showed mole-
cule-speciﬁc developmental variations in their E-CSF/E-serum ratio.
The highest E-CSF/E-serum ratio for FGF2 was detected at E3 and E4,
the developmental period inwhich this growth factor acts from the E-
CSF to inﬂuence neuroepithelial progenitor cell proliferation. In this
period, FGF2 also contributes to triggering brain neurogenesis (Martin
et al., 2006). In the same way, the maximum E-CSF/E-serum ratio for
RBP was detected at E4 but not at E3, coinciding with its suggested
activity in retinol transport to the E-CSF (Parada et al., 2008). The E-
CSF/E-serum ratio of ovalbumin–a protein whose role during devel-
opment has not been associated with morphogenesis or neurogen-
esis–does not vary signiﬁcantly from E3 to E5. Taken together, these
results suggest that the transfer of proteins across the blood–CSF
interface is developmentally regulated and molecule-speciﬁc as early
as the initiation of brain neurogenesis, thus indicating that this
interface has a barrier function.
The transfer ratio of microinjected endogenous proteins does not alter
their concentration within the E-CSF
One of the known roles of blood–CSF interface systems with a
barrier function, such as in the foetus and adult choroid plexus, is to
act as a kidney-like organ that regulates the concentration of
potentially harmful molecules within the CSF, including cellular and
metabolic debris, excess ions and water, drugs and proteins (for
reviews, see Johanson et al., 1999b; Emerich et al., 2005). Our results
show that when the concentration of normal E-CSF molecules is
experimentally increased, i.e. when additional molecules are micro-injected into the cephalic cavities, they are rapidly removed from the
cavities and subsequently from the embryo serum, in order to
maintain the homeostasis of these ﬂuids. Moreover, when the
concentration of suchmolecules within the E-serum is experimentally
increased, their overall concentration within this intracavitary ﬂuid
does not increase, although some of them (i.e. RBP, FGF2 and
ovalbumin) are effectively transferred to the E-CSF to play their
normal role in CNS development. The embryo rapidly eliminates
excess proteins from the E-serum. Therefore, the period inwhich their
concentration within the E-CSF may be above normal levels is very
short. However, these results suggest that certain mechanisms control
the concentration of molecules within the E-CSF (and also within the
E-serum). Such mechanisms can detect protein concentration and
eliminate any excess. Thus, these results support the existence of a
barrier function in the blood–CSF interface as early as the beginning of
brain neurogenesis.
The transfer of exogenous microinjected proteins is restricted and
protein-speciﬁc
As mentioned above, previous works on BBB function showed that
the permeability of the blood-brain interface to HRP begins to
decrease at E12–E14 (Wakai and Hirokawa, 1978) in chick embryos.
Thus, younger embryos may have a free diffusion system for protein
transfer. This apparently contradicts the above suggestion that the
transfer of proteins across the blood–CSF interface is regulated by a
barrier function. To evaluate this possibility, in this study we
examined the transfer of several different proteins that are not
normally present in chick embryos or within the analysed ﬂuids,
including HRP. As described byWakai and Hirokawa (1978), whenHRP
is supplied to the blood stream it is transferred to the E-CSF with no
apparent restrictions, which supports the free diffusion hypothesis.
However, this was the only exogenous molecule in the study that
behaved in this way. All the other exogenous molecules, including
BSA, GST/Adh, MHC and mouse IgGs, did not cross the blood–CSF
interface. Apart from immunoglobulins, all of the molecules were
eliminated by the allantoids shortly after microinjection. Two
different explanations may account for this lack of blood–CSF interface
transfer: (1) the allantoids remove these molecules very rapidly and
they do not have the chance to cross the interface, irrespective of any
transport control mechanisms; and (2) the speciﬁc proteins to be
transferred at this interface are regulated, and these particular
molecules cannot be transported. From our results, it is obvious that
the allantoids remove thesemolecules very rapidly, but they remain in
the E-serum for a certain period (more than 10 min). We demon-
strated that FGF2, RBP and ovalbumin, coupled to FITC to distinguish
them from the endogenous molecules, are effectively transferred
across the blood–CSF interface in a very short time, much shorter than
10 min. This suggests a precisely regulated active transport mechan-
ism across blood–CSF interface that only allows certain molecules to
cross—or alternatively does not allow other molecules to cross. In this
respect, it is known that in foetuses and adults the tissues involved in
the barrier blood–CSF interface have numerous speciﬁc transport
systems, including a broad array of receptors (Chodobski and
Szmydynger-Chodobska, 2001; Emerich et al., 2005). The description
of the nature of the speciﬁc transport systems acting at the embryo
blood–CSF interface requires further analysis.
Likewise, when these exogenous molecules are microinjected into
the cephalic cavities, they are rapidly transferred to the blood stream
by means of the kidney-like function of the blood–CSF interface.
However, there are two signiﬁcant exceptions: HRP and mouse IgG,
which are not eliminated from the E-CSF. The issue of why HRP is
transferred from the E-serum to the E-CSF but not in the opposite
direction still needs to be discussed. Although E-CSF contains mole-
cules with peroxidase activity (Parada et al., 2006) that may account
for the exceptional embryo transfer of HRP, its amino acid sequence is
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IgGs, although they are not transferred from the E-serum to the E-CSF,
their removal from the E-serum is much slower than that of BSA, GST/
Adh and MHC. Moreover, there is little transfer of IgGs from the E-CSF
to the E-serum. This lack of IgGs transport is probably not due to a size
restriction transport mechanism, as MHC–which has a similar
molecular mass–is rapidly removed from the brain cavities. The
differential transport dynamics of immunoglobulins with respect to
BSA, GST/Adh andMHCmay be due to the fact that chick embryos also
contain certain types of immunoglobulins (i.e. IgY) which are taken up
from the egg reservoir. Although IgY was found within the E-serum, it
was not transferred to the E-CSF at the analysed developmental stages.
Thus, the normal levels of immunoglobulins within the E-serum may
explain the slower rate of elimination of IgGs from this ﬂuid. In the
same way, the lack of IgY transfer to the E-CSF as well as the lack of
transfer of the injected IgG to the E-serum suggest that the embryo
blood–CSF interface is completely impermeable to immunoglobulins.
Taken together, the results presented in this paper indicate that the
transfer of proteins across the blood–CSF interface is regulated
differentially depending on each speciﬁc molecule. In addition, the
allantoids also contribute differentially to the elimination of proteins
from the blood stream. In conclusion, the transport dynamics of all the
analysed molecules indicate that the blood–CSF interface has a barrier
function as early as E4 in chick embryos. This controls which
molecules are transferred across the interface, as well as the rate of
transport.
Blood–CSF interface for protein transfer at E4 is located in the brain stem
The different approaches used in this study to analyse the location
of the blood–CSF interface reveal that during the developmental
period E3 to E4 the blood–CSF transfer site for proteins is limited to a
very speciﬁc area located in the brain stem, speciﬁcally in the ventral
mesencephalic and rhombencephalic neuroectoderm lateral to the
ventral midline. BDA3000 microinjection into the cephalic cavities
shows that at E3 (HH20) protein molecules are transferred by most, if
not all, neuroectodermal cells all along the cephalic neuroepithelium,
which is physiologically sealed. Concomitantly, ovalbumin coupled to
Evitags® microinjected into the outﬂow of the heart showed that
several different capillaries surrounding the brain cavities are in-
volved in such transfer. However, at E4 (HH23), an analysis of these
tracers and of the transport of some other molecules (BSA, RBP and
ovalbumin) by immunohistochemical procedures revealed that the
area of transfer was restricted to a speciﬁc zone of the embryo located
in the brain stem in the ventral mesencephalic and prosencephalic
neuroectoderm, lateral to the ventral midline. Interestingly, the blood
vessels in this area are the ones that show the ﬁrst HT7 antigen
expression from E6 on. HT7 is a chick-speciﬁc antigen for endothelial
cells fulﬁlling barrier functions (Bertossi et al., 2002). This suggests
that the barrier function reported in this paper precedes the reported
detection of HT7 in these blood vessels.
Interestingly, this area does not coincide with the zones from
which the different adult choroid plexuses form in a subsequent
developmental stage (Bellairs and Osmond, 2005). However, in
mouse embryos, it has been reported that the ﬁrst capillaries which
penetrate the neuroectoderm localise precisely in these areas, the
brain stem of the mesencephalon and rhombencephalon, and that
they do so from the ventro-lateral side, starting at mouse E10, just
after the closure of the anterior neuropore (CNS-speciﬁc development
of a mouse embryo at E10 approximately corresponds to that of an
E3–3.5 chick embryo) (Herken et al., 1989). All these data indicate
that this area is a transient place that fulﬁls blood–CSF barrier func-
tions. Thus, it contributes to manufacturing E-CSF in this develop-
mental stage.
The results using cultured explants in which RBP-FITC was laid
onto themesechyma underlying the neuroectoderm of the brain stem,or onto the mesencephalic dorsal neuroectoderm, indicate that, after
the restriction of the area of protein transfer across the blood–CSF
interface that occurred between E3 and E4, the neuroectodermal cells
located close to the aforementioned blood vessels become the only
ones capable of protein transport. This suggests that both the blood
vessels and the ventral neuroectoderm of the brain stem are involved
in barrier functions. In this respect, the presence of HT7 positive
neuroblasts has been described at E5 in this precise location (Bertossi
et al., 2002).
In conclusion, this study indicates that protein homeostasis of the
E-CSF at the beginning of brain neurogenesis is controlled by the
barrier function of a blood–CSF interface. This regulates the proteins
that are transferred in a protein-speciﬁc manner and also controls
their concentration within the E-CSF. Moreover, this study shows that
after closure of the anterior neuropore and during the initiation of
brain primary neurogenesis, this blood–CSF interface with barrier
functions is located in the brain stem, in the ventral mesencephalon
and prosencephalon lateral to the ventral midline. As mentioned
above, the description of the nature of the speciﬁc transport systems
acting at the embryo blood–CSF interface requires further analysis. We
can also conclude that this blood–CSF interface contributes to the
crucial role of E-CSF in CNS development by regulating its speciﬁc
composition.
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